<DOC>
	<DOC>NCT00149994</DOC>
	<brief_summary>The purpose of this study is to determine whether cyclosporine A (in a micro emulsion formulation) monitored by sample taken 2 hour after oral dose (C-2h) will show equivalent or superior efficacy compared to tacrolimus monitored by pre-dose blood concentration (C-0h). In addition this study will assess the safety and tolerability of a cyclosporine A regimen based on C-2h monitoring in comparison to the standard tacrolimus regimen.</brief_summary>
	<brief_title>Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<criteria>About to undergo a primary liver transplant (including living donor, nonheart beating donor and split liver). Age between 18 and 75 years. Expected to be able to receive the first oral dose of CNI within the first 24 hours posttransplantation (Tx) This is a multiorgan transplant or if the patient has previously been transplanted with any other organ. Urine production is &lt;200 ml within 12 hours after reperfusion of the graft Severe coexisting disease is present or if any unstable medical condition is present which could affect the study objectives. Other protocoldefined exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Liver transplant, adults, C2 monitoring</keyword>
</DOC>